Spero Therapeutics (NASDAQ:SPRO) Issues Quarterly Earnings Results

Spero Therapeutics (NASDAQ:SPRO) announced its quarterly earnings data on Thursday. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03), Zacks reports. Spero Therapeutics had a return on equity of 4.03% and a net margin of 3.30%.

Spero Therapeutics Stock Performance

Spero Therapeutics stock traded down $0.03 during trading hours on Thursday, hitting $0.86. 82,304 shares of the stock were exchanged, compared to its average volume of 190,327. Spero Therapeutics has a 12 month low of $0.73 and a 12 month high of $1.81. The business’s 50-day moving average is $0.82 and its two-hundred day moving average is $1.06. The stock has a market capitalization of $46.89 million, a P/E ratio of 12.29 and a beta of 0.68.

Insider Transactions at Spero Therapeutics

In related news, Director Ankit Mahadevia sold 69,219 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total value of $53,990.82. Following the completion of the sale, the director now owns 689,866 shares of the company’s stock, valued at $538,095.48. This trade represents a 9.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Sath Shukla sold 155,333 shares of the company’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total value of $121,159.74. Following the transaction, the chief executive officer now directly owns 1,736,883 shares in the company, valued at approximately $1,354,768.74. This represents a 8.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 245,241 shares of company stock valued at $191,288 in the last three months. 4.52% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

SPRO has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Spero Therapeutics in a research report on Thursday, January 30th. Evercore ISI lowered Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective on the stock. in a research note on Friday, December 20th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.